Antithrombotic therapy with low molecular weight heparins in renal insufficiency;Antithrombotische therapie mit niedermolekularen heparinen bei niereninsuffizienz

Journal fur Kardiologie

Volumn 11, Issue 7-8, 2004, Pages 313-316

  Darius, H ^a   Hester, K ^b   Sanderink, G J ^c   Paar, W D ^b  

^a VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CREATININE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG ELIMINATION; GERMANY; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY FAILURE; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 3843099382     PISSN: 10240098     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Samama MM, Bara L, Gerotziafas GT. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis 1994; 24: 105-17.
2. Warkentin TE, Levine MM, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
3. Weitz I. Low-Molecular-Weight Heparins. N Engl J Med 1997; 337: 688-98.
4. Ahmad S, Jeske WP, Ma O, Walenga JM, Fareed J. Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist. Thromb Res 2001; 102: 143-51.
5. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular weight heparins and UFH in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 269-77.
6. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160: 181-8.
7. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-601.
8. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell G, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-52.
9. Antman EM, Cohen MD, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E. Assessment of the treatment effect of enoxaparin for unstable angina/Non-Q-wave infarction-TIMI 11B-ESSENCE Meta-Analysis. Circulation 1999; 100: 1602-8.
10. Goodman SG, Cohen M, Bigonzi F, Gurfinkel EP, Radley DR, Le Iouer V, Fromell GJ, Demers C, Turpie AG, Califf RM, Fox KA, Langer A. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 2000; 36: 693-8.
11. Eikelboom JW, Anand SS, Malmberg K, Weitz JJ, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355: 1936-42.
12. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Sem Thromb Hemost 2000; 26(S1): 31-8.
13. Kereiakes DJ, Montalescot G, Antman EM, Cohen M, Darius H, Ferguson JJ, Grines C, Karsch KR, Klienman MS, Moliterno DJ, Steg PG, Teirstein P, Van de Werf F, Wallentin L. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: An expert consensus. Am Heart J 2002; 144: 615-24.
14. Siguret V, Pautas E, Février M, Wipff C, Durand-Gasselin, Laurent M, Andreux JP, d'Urso M, Gaussem P. Elderly patients treated with tinzaparin (Innohep®) administered once daily (175 Anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000; 84: 800-4.
15. Mismetti P, Laporte-Simitsidis S, Navarro C, Sié P, d'Azemar P, Mecciari J, Duret JP, Gaud C, Decousus H, Boneu B. Aging and venous thromboembolism influence the pharmacodynamics of the anti-Xa and anti-thrombin activities of a low molecular weight heparin (Nadroparin). Thromb Haemost 1998; 79: 1162-5.
16. Cadroy Y, Pourrat J, Baladre MF, Saivin S, Houin G, Montastruc JL, Vernier I, Boneu B. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991; 63: 385-90.
17. Sanderink GJ, Guimart CG, Ozoux MI, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002; 105: 225-31.
18. Cestac P, Bagheri H, Lapeyre-Mestre M, Sié P, Fouladi A, Maupas E, Léger P, Fontan B, Massip P, Montastruc JP. Utilisation and safety of low molecular weight heparins. Drug Safety 2003; 26: 197-207.
19. Berkowitz SD, Stinnett S, Cohen M, Fromell GJ, Bigonzi F, on behalf of the ESSENCE Investigators. Prospective comparison of hemorrhagic complications after treatment with Enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol 2001; 88: 1230-4.
20. Eagle K. Lessons from GRACE: the Global Registry of Acute Coronary Events. Eur Heart J 2002; 4: Suppl. E: E24-E31.
21. Collet JP, Agnelli G, Van de Werf FJ, Brieger D, Gurfinkel EP, Lopez-Sendon J, Gowda N, Montalescot, on behalf of the GRACE Investigators. J Am Coll Cardiol 2003; 41: Ab 1026-101.
22. Bjornsson TD, Wolfram KM, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther 1982; 31: 104-13.
23. Reddan D, Szczech LA, O'Shea S, Califf RM. Anticoagulation in acute cardiac care in patients with chronic kidney disease. Am Heart J 2003; 145: 584-94.
24. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Int Med 2002; 162: 2605-9.
25. Gulba DC, Lankes W, Lopez-Sendon J, Lim MJ, Kline-Rogers E, Herbrandt RG, Aler D, Kuznetsova P, Metha R. Reduced risk of bleeding complications in patients with renal insufficiency and acute coronary syndromes treated with low-molecular-weight heparin: insights from GRACE. Circulation 2002; 106(S): Ab 1683.
26. Collet JP, Montalescot G, Choussat R, Lison L, Ankri A. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol 2001; 80: 81-2.
27. Smith BS, Gandhi PJ. Pharmacokinetics and Pharmcodynamics of Low-Molecular-Weight Heparins and Glycoprotein IIb/IIIa Receptor Antagonists in Renal Failure. J Thromb Thrombolysis 2001; 11: 39-48.
28. Abbate R, Gori AM, Farsi A, Attanasio M, Pepe G. Monitoring of low-molecular-weight heparins in cardiovascular disease. Am J Cardiol 1998; 82: 33L-36L
29. Cockgroft DW, Gault MH. Predection of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.